Article information
Abstract
Ischemic stroke is a serious neurological condition that requires urgent attention. As a time-dependent disease, acute stroke management must be coordinated and effective to provide the best treatment as early as possible. The treatment of the acute phase of ischemic stroke includes general measures to ensure patient hemodynamic stability, the use of reperfusion therapies (intravenous thrombolytics and mechanical thrombectomy), improving cerebral protection by monitoring the homeostasis of certain variables as blood pressure, glycemia, temperature, or oxygenation, as well as preventing cerebral and systemic complications. Also, it is necessary an early planning of comprehensive rehabilitation. To prevent early recurrences, control of vascular risk factors and antithrombotic treatment is recommended. The management of patients with acute ischemic stroke aims to reverse initial symptoms, to prevent further brain damage, improve functional outcomes and avoid ischemic recurrences.
Keywords:
Ischemic stroke
Code stroke
Stroke unit
Acute reperfusion therapy
Brain protection
Complications of the acute phase of stroke
Resumen
El ictus isquémico es una enfermedad neurológica grave que precisa una atención urgente. Al ser una enfermedad dependiente del tiempo, la asistencia debe ser coordinada y eficaz para que ofrezca el tratamiento adecuado de la forma más precoz posible. El tratamiento de la fase aguda incluye unas medidas generales para garantizar la estabilidad hemodinámica del paciente, el uso de terapias de reperfusión (trombolíticos intravenosos y tratamiento endovascular mediante trombectomía mecánica) y la contribución a la protección cerebral mediante el control de presión arterial, glucemia, temperatura y oxigenación, así como prevenir complicaciones cerebrales y sistémicas. Se debe planificar de manera precoz el tratamiento rehabilitador del paciente. Para evitar las recurrencias precoces se recomienda tratamiento antitrombótico según la etiología del ictus y el control de los factores de riesgo vascular. Todas estas medidas tienen como objetivo revertir los síntomas iniciales, evitar que progrese la lesión, mejorar la situación funcional del paciente y evitar recurrencias.
Palabras clave:
Ictus isquémico
Código ictus
Unidad de ictus
Tratamiento reperfusor
Protección cerebral
Complicaciones fase aguda ictus
Article
These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
References
[1]
E. Stevens, E. Emmett, Y. Wang, C. McKevitt, C. Wolfe.
The burden of stroke in Europe.
Stroke Alliance for Europe, (2017),
[2]
B. Norrving, J. Barrick, A. Davalos, M. Dichgans, C. Cordonnier, A. Guekht, et al.
Action plan for stroke in Europe 2018–2030.
Eur Stroke J, 3 (2018), pp. 309
[3]
Plan de atención de los pacientes con ictus en la Comunidad de Madrid.
Dirección General de Proceso Integrado de Salud Servicio Madrileño de Salud.
Consejería de Sanidad, (2021),
[4]
P. Langhorne, S. Ramachandra, Collaboration SUT.
Organised inpatient (stroke unit) care for stroke: network meta-analysis.
Cochrane Database Syst Rev, (2020), pp. 4
[5]
E. Díez-Tejedor, B. Fuentes.
Acute care in stroke: do stroke units make the difference?.
Cerebrovasc Dis, 11 (2001), pp. 31-39
[6]
S. Pastor, E. De Celis, I. Losantos Garciá, M. Alonso De Leciñana, B. Fuentes, E. Diéz-Tejedor.
Development of the Madrid Stroke Programme: milestones and changes in stroke trends and mortality from 1997 to 2017.
Neuroepidemiology, 55 (2021), pp. 135-140
[7]
National Institute of Neurological Disorders, Stroke rt-PA, Stroke Study Group.
Tissue plasminogen activator for acute ischemic stroke.
N Engl J Med, 333 (1995), pp. 1581-1588
[8]
W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Dávalos, D. Guidetti, et al.
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
N Engl J Med, 359 (2008), pp. 1317-1329
[9]
J. Emberson, K.R. Lees, P. Lyden, L. Blackwell, G. Albers, E. Bluhmki, et al.
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
Lancet, 384 (2014), pp. 1929-1935
[10]
W.J. Powers, A.A. Rabinstein, T. Ackerson, O.M. Adeoye, N.C. Bambakidis, K. Becker, et al.
Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
Stroke, 50 (2019), pp. E344-E418
[11]
E. Berge, W. Whiteley, H. Audebert, G.M.De Marchis, A.C. Fonseca, C. Padiglioni, et al.
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.
Eur Stroke J, 6 (2021), pp. I-LXII
[12]
S. Yaghi, J.Z. Willey, B. Cucchiara, J.N. Goldstein, N.R. Gonzales, P. Khatri, et al.
Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association.
Stroke, 48 (2017), pp. e343-61
[13]
J. Sun, C. Lam, L. Christie, C. Blair, X. Li, F. Werdiger, et al.
Risk factors of hemorrhagic transformation in acute ischaemic stroke: a systematic review and meta-analysis.
Front Neurol, 14 (2023),
[14]
R. Hurford, S. Rezvani, M. Kreimei, A. Herbert, A. Vail, A.R. Parry-Jones, et al.
Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke.
J Neurol Neurosurg Psychiatry, 86 (2015), pp. 520-523
[15]
A.M. Burgos, J.L. Saver.
Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials.
Stroke, 50 (2019), pp. 2156-2162
[16]
B.K. Menon, B.H. Buck, N. Singh, Y. Deschaintre, M.A. Almekhlafi, S.B. Coutts, et al.
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Lancet, 400 (2022), pp. 161-169
[17]
B.C.V. Campbell, P.J. Mitchell, L. Churilov, N. Yassi, T.J. Kleinig, R.J. Dowling, et al.
Tenecteplase versus alteplase before thrombectomy for ischemic stroke.
N Engl J Med, 378 (2018), pp. 1573-1582
[18]
S. Alamowitch, G. Turc, L. Palaiodimou, A. Bivard, A. Cameron, G.M. De Marchis, et al.
European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke.
Eur Stroke J, 8 (2023), pp. 8-54
[19]
H. Ma, B.C.V. Campbell, M.W. Parsons, L. Churilov, C.R. Levi, C. Hsu, et al.
Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke.
N Engl J Med, 380 (2019), pp. 1795-1803
[20]
B.C.V. Campbell, H. Ma, P.A. Ringleb, M.W. Parsons, L. Churilov, M. Bendszus, et al.
Extending thrombolysis to 4.5-9h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
Lancet, 394 (2019), pp. 139-147
[21]
G. Thomalla, C.Z. Simonsen, F. Boutitie, G. Andersen, Y. Berthezene, B. Cheng, et al.
MRI-guided thrombolysis for stroke with unknown time of onset.
N Engl J Med, 379 (2018), pp. 611-622
[22]
B.C.V. Campbell, P.J. Mitchell, T.J. Kleinig, H.M. Dewey, L. Churilov, N. Yassi, et al.
Endovascular therapy for ischemic stroke with perfusion-imaging selection.
N Engl J Med, 372 (2015), pp. 1009-1018
[23]
M. Goyal, A.M. Demchuk, B.K. Menon, M. Eesa, J.L. Rempel, J. Thornton, et al.
Randomized assessment of rapid endovascular treatment of ischemic stroke.
N Engl J Med, 372 (2015), pp. 1019-1030
[24]
T.G. Jovin, A. Chamorro, E. Cobo, M.A. de Miquel, C.A. Molina, A. Rovira, et al.
Thrombectomy within 8 hours after symptom onset in ischemic stroke.
N Engl J Med, 372 (2015), pp. 2296-2306
[25]
J.L. Saver, M. Goyal, A. Bonafe, H.-C. Diener, E.I. Levy, V.M. Pereira, et al.
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.
N Engl J Med, 372 (2015), pp. 2285-2295
[26]
O.A. Berkhemer, P.S.S. Fransen, D. Beumer, L.A. van den Berg, H.F. Lingsma, A.J. Yoo, et al.
A randomized trial of intraarterial treatment for acute ischemic stroke.
N Engl J Med, 372 (2015), pp. 11-20
[27]
M. Goyal, B.K. Menon, W.H. Van Zwam, D.W.J. Dippel, P.J. Mitchell, A.M. Demchuk, et al.
Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
Lancet, 387 (2016), pp. 1723-1731
[28]
G.W. Albers, M.P. Marks, S. Kemp, S. Christensen, J.P. Tsai, S. Ortega-Gutierrez, et al.
Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging.
N Engl J Med, 378 (2018), pp. 708-718
[29]
R.G. Nogueira, A.P. Jadhav, D.C. Haussen, A. Bonafe, R.F. Budzik, P. Bhuva, et al.
Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct.
N Engl J Med, 378 (2018), pp. 11-21
[30]
C. Tao, R.G. Nogueira, Y. Zhu, J. Sun, H. Han, G. Yuan, et al.
Trial of endovascular treatment of acute basilar-artery occlusion.
N Engl J Med, 387 (2022), pp. 1361-1372
[31]
T.G. Jovin, C. Li, L. Wu, C. Wu, J. Chen, C. Jiang, et al.
Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion.
N Engl J Med, 387 (2022), pp. 1373-1384
[32]
P.A. Barber, A.M. Demchuk, J. Zhang, A.M. Buchan.
Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy.
Lancet, 355 (2000), pp. 1670-1674
[33]
X. Huo, G. Ma, X. Tong, X. Zhang, Y. Pan, T.N. Nguyen, et al.
Trial of endovascular therapy for acute ischemic stroke with large infarct.
N Engl J Med, 388 (2023), pp. 1272-1283
[34]
A. Sarraj, A.E. Hassan, M.G. Abraham, S. Ortega-Gutierrez, S.E. Kasner, M.S. Hussain, et al.
Trial of endovascular thrombectomy for large ischemic strokes.
N Engl J Med, 388 (2023), pp. 1259-1271
[35]
G. Turc, P. Bhogal, U. Fischer, P. Khatri, K. Lobotesis, M. El Mazighi, et al.
European Stroke Organisation (ESO)–European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischaemic stroke endorsed by Stroke Alliance for Europe (SAFE).
Eur Stroke J, 4 (2019), pp. 6-12
[36]
P.J. Mitchell, B. Yan, L. Churilov, R.J. Dowling, S.J. Bush, A. Bivard, et al.
Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial.
Lancet, 400 (2022), pp. 116-125
[37]
U. Fischer, J. Kaesmacher, D. Strbian, O. Eker, C. Cognard, P.S. Plattner, et al.
Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial.
Lancet, 400 (2022), pp. 104-115
[38]
E.H. Ngankou, B. Gory, G. Marnat, S. Richard, R. Bourcier, I. Sibon, et al.
Thrombectomy complications in large vessel occlusions: incidence, predictors, and clinical impact in the ETIS Registry.
Stroke, 52 (2021), pp. E764-8
[39]
E. Díez-Tejedor, B. Fuentes.
Homeostasis as basis of acute stroke treatment: stroke units are the key.
Cerebrovasc Dis, 20 (2005), pp. 129-134
[40]
S. Middleton, P. McElduff, J. Ward, J.M. Grimshaw, S. Dale, C. D’Este, et al.
Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial.
Lancet, 378 (2011), pp. 1699-1706
[41]
E.C. Sandset, C.S. Anderson, P.M. Bath, H. Christensen, U. Fischer, D. Gąsecki, et al.
European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage.
Eur Stroke J, 6 (2021), pp. XLVIII
[42]
K. Malhotra, N. Ahmed, A. Filippatou, A.H. Katsanos, N. Goyal, K. Tsioufis, et al.
Association of elevated blood pressure levels with outcomes in acute ischemic stroke patients treated with intravenous thrombolysis: a systematic review and meta-analysis.
J Stroke, 21 (2019), pp. 78-90
[43]
B. Fuentes, B.E. Sanz-Cuesta, M. Gutiérrez-Fernández, P. Martínez-Sánchez, A. Lisbona, R. Madero-Jarabo, et al.
Glycemia in Acute Stroke II study: a call to improve post-stroke hyperglycemia management in clinical practice.
Eur J Neurol, 24 (2017), pp. 1091-1098
[44]
B. Fuentes, G. Ntaios, J. Putaala, B. Thomas, G. Turc, E. Díez-Tejedor.
European Stroke Organisation (ESO) guidelines on glycaemia management in acute stroke.
Eur Stroke J, 3 (2018), pp. 5
[45]
N.A. Elsayed, G. Aleppo, V.R. Aroda, R.R. Bannuru, F.M. Brown, D. Bruemmer, et al.
16. Diabetes care in the hospital: standards of care in diabetes—2023.
Diabetes Care, 46 (2023), pp. S267-78
[46]
H. Reinink, E. Jüttler, W. Hacke, J. Hofmeijer, E. Vicaut, K. Vahedi, et al.
Surgical decompression for space-occupying hemispheric infarction: a systematic review and individual patient meta-analysis of randomized clinical trials.
JAMA Neurol, 78 (2021), pp. 208-216
[47]
H.B. van der Worp, J. Hofmeijer, E. Jüttler, A. Lal, P. Michel, P. Santalucia, et al.
European Stroke Organisation (ESO) guidelines on the management of space-occupying brain infarction.
Eur Stroke J, 6 (2021), pp. XC-CX
[48]
E.F.M. Wijdicks, K.N. Sheth, B.S. Carter, D.M. Greer, S.E. Kasner, W.T. Kimberly, et al.
Recommendations for the management of cerebral and cerebellar infarction with swelling.
Stroke, 45 (2014), pp. 1222-1238
[49]
J.M. Hong, D.S. Kim, M. Kim.
Hemorrhagic transformation after ischemic stroke: mechanisms and management.
Front Neurol, 12 (2021),
[50]
M. Holtkamp, E. Beghi, F. Benninger, R. Kälviäinen, R. Rocamora, H. Christensen.
European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy.
Eur Stroke J, 2 (2017), pp. 103-115
[51]
V. Rethnam, K.S. Hayward, J. Bernhardt, L. Churilov.
Early mobilization after stroke: do clinical practice guidelines support clinicians’ decision-making?.
Front Neurol, 12 (2021), pp. 33
[52]
E. Noé, A. Gómez, M. Bernabeu, I. Quemada, R. Rodríguez, T. Pérez, et al.
Guía: Principios básicos de la neurorrehabilitación del paciente con daño cerebral adquirido. Recomendaciones de la Sociedad Española de Neurorrehabilitación.
Neurología, (2021),
[53]
J. Dawson, Y. Béjot, L.M. Christensen, G.M. De Marchis, M. Dichgans, G. Hagberg, et al.
European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack.
Eur Stroke J, 7 (2022), pp. I-II
[54]
C.J.M. Klijn, M. Paciaroni, E. Berge, E. Korompoki, J. Kõrv, A. Lal, et al.
Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.
Eur Stroke J, 4 (2019), pp. 198-223
[55]
Y. Wang, Y. Wang, X. Zhao, L. Liu, D. Wang, C. Wang, et al.
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
N Engl J Med, 369 (2013), pp. 11-19
[56]
S.C. Johnston, J.D. Easton, M. Farrant, W. Barsan, R.A. Conwit, J.J. Elm, et al.
Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.
N Engl J Med, 379 (2018), pp. 215-225
[57]
Y. Pan, J.J. Elm, H. Li, J.D. Easton, Y. Wang, M. Farrant, et al.
Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials.
JAMA Neurol, 76 (2019), pp. 1466
[58]
D.L. Brown, D.A. Levine, K. Albright, M.K. Kapral, L.Y. Leung, M.J. Reeves, et al.
Benefits and risks of dual versus single antiplatelet therapy for secondary stroke prevention: a systematic review for the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack.
Stroke, 52 (2021), pp. e468-e479
[59]
J. Dawson, Á Merwick, A. Webb, M. Dennis, J. Ferrari, A.C. Fonseca.
European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA.
Eur Stroke J, 6 (2021), pp. 2
[60]
B. Flusty, A. de Havenon, S. Prabhakaran, D.S. Liebeskind, S. Yaghi.
Intracranial atherosclerosis treatment: Past, present, and future.
Stroke, (2020), pp. E49-53
